Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme
Myrthe J. van Dijk(Utrecht University), Richard van Wijk(Utrecht University), Minke A.E. Rab(Utrecht University), Kevin H.M. Kuo(University Health Network), Jonathan R.A. de Wilde(Utrecht University), Eduard J. van Beers(Utrecht University), Andreas Glenthøj(University of Copenhagen), Marije Bartels(University Medical Center Utrecht)
Cited by 20
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162